Similar articles

• Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up.

  Andriole GL, Crawford ED, Grubb RL 3rd, Buys SS, Chia D, Church TR, Fouad MN, Isaacs C, Kvale PA, Reding DJ, Weissfeld JL, Yokochi LA, O'Brien B, Ragard LR, Clapp JD, Rathmell JM, Riley TL, Hsing AW, Izmirlian G, Pinsky PF, Kramer BS, Miller AB, Gohagan JK, Prorok PC; PLCO Project Team. Andriole GL, et al. J Natl Cancer Inst. 2012 Jan 18;104(2):125-32. doi: 10.1093/jnci/djr500. Epub 2012 Jan 6. J Natl Cancer Inst. 2012. PMID: 22228146 Free PMC article. Clinical Trial.
• Extended follow-up for prostate cancer incidence and mortality among participants in the Prostate, Lung, Colorectal and Ovarian randomized cancer screening trial.

  Pinsky PF, Miller E, Prorok P, Grubb R, Crawford ED, Andriole G. Pinsky PF, et al. BJU Int. 2019 May;123(5):854-860. doi: 10.1111/bju.14580. Epub 2018 Nov 2. BJU Int. 2019. PMID: 30288918 Free PMC article. Clinical Trial.
• [Screening and prevention of prostate cancer].

  Roosen A. Roosen A. MMW Fortschr Med. 2010 May 13;152(19):37-9. doi: 10.1007/BF03366554. MMW Fortschr Med. 2010. PMID: 20557000 German. No abstract available.
• Guideline of guidelines: prostate cancer screening.

  Loeb S. Loeb S. BJU Int. 2014 Sep;114(3):323-5. doi: 10.1111/bju.12854. BJU Int. 2014. PMID: 24981126 Review. No abstract available.
• [Screening for prostate cancer using prostate-specific antigen (PSA) : A commentary on a systematic review and meta-analysis].

  Borkowetz A. Borkowetz A. Urologe A. 2019 Aug;58(8):925-928. doi: 10.1007/s00120-019-0990-6. Urologe A. 2019. PMID: 31240375 German. No abstract available.